^
    19h
    A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis (clinicaltrials.gov)
    P=N/A, N=180, Completed, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Sep 2029 --> Dec 2025 | Trial primary completion date: Sep 2027 --> Sep 2025 | Enrolling by invitation --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    24h
    Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=13, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    capecitabine • Libtayo (cemiplimab-rwlc)
    1d
    An integrative pharmacovigilance, network toxicology and molecular docking study on drug-induced cheilitis. (PubMed, Front Pharmacol)
    Thirty-eight pharmaceuticals demonstrated significant associations with cheilitis, with isotretinoin being the most frequently reported (ROR = 42.61) and crisaborole exhibiting the most pronounced signal (ROR = 550.48)...Molecular docking studies indicated strong binding affinities (ranging from -8.1 to -6.2 kcal/mol), particularly for the afatinib-EGFR and capecitabine-IL-6 interactions...ADMET profiling predicted a high risk of drug-induced liver injury for four compounds, while lamotrigine demonstrated a favorable safety profile. This integrative framework connects population-level indicators with mechanistic forecasts, providing a translational model for comprehending, predicting, and managing drug-induced cheilitis.
    Journal • Adverse events
    |
    EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL17A (Interleukin 17A)
    |
    Gilotrif (afatinib) • capecitabine
    2d
    POCHI: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (clinicaltrials.gov)
    P2, N=55, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
    3d
    Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil. (PubMed, Cell Death Dis)
    5-Fluorouracil (5-FU) and its prodrugs are widely used drugs for chemotherapy in various cancers. In conclusion, our study reveals that everolimus sensitizes breast cancer to fluoropyrimidines by destabilizing TYMS through modulation of its O-GlcNAcylation. These findings support a promising combination strategy to improve the therapeutic efficacy of 5-FU and capecitabine in breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYMS (Thymidylate Synthetase) • OGT (O-linked N-acetylglucosamine (GlcNAc) transferase)
    |
    HER-2 negative
    |
    5-fluorouracil • everolimus • capecitabine
    4d
    A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC (clinicaltrials.gov)
    P2, N=28, Completed, Asan Medical Center | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    cisplatin • capecitabine • Ontruzant (trastuzumab-dttb)
    4d
    Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Vejle Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    4d
    Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • capecitabine • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    4d
    Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Tyvyt (sintilimab) • capecitabine • Aidixi (disitamab vedotin)
    5d
    Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. (PubMed, ESMO Real World Data Digit Oncol)
    The most common regimens included capecitabine and everolimus plus exemestane. Multivariable analysis showed that younger age, prior fulvestrant use, and shorter CDK4/6i duration were associated with CHT choice...Treatment decisions are influenced by clinical history and patient characteristics. These findings underscore the need for personalized approaches and molecular profiling to guide post-CDK4/6i therapy in HR-positive/HER2-negative MBC.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    |
    everolimus • capecitabine • fulvestrant • exemestane
    5d
    Pembrolizumab plus chemotherapy following lack of response to nivolumab-based therapy in MSI-High/dMMR advanced gastric cancer: a case report. (PubMed, Int Cancer Conf J)
    He subsequently received ramucirumab-based therapy, paclitaxel, and irinotecan...Pembrolizumab combined with capecitabine and oxaliplatin (CAPOX) was initiated as fifth-line therapy, resulting in notable regression of hepatic and nodal metastases. This case underscores the clinical importance of early MSI/MMR and genomic testing and suggests that re-administration of ICI plus chemotherapy may be a therapeutic option for selected patients with advanced gastric cancer who initially show limited response to ICI-based therapy.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • paclitaxel • capecitabine • Cyramza (ramucirumab) • oxaliplatin • irinotecan • Teysuno (gimeracil/oteracil/tegafur)
    5d
    MRD-ATLAS-III: Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment (clinicaltrials.gov)
    P3, N=304, Not yet recruiting, Shanghai Zhongshan Hospital
    New P3 trial • Minimal residual disease • Circulating tumor DNA
    |
    5-fluorouracil • capecitabine • oxaliplatin